The Global Biologics Market Size is valued at 382.17 billion in 2022 and is predicted to reach 718.97 billion by the year 2031 at a 7.50% CAGR during the forecast period for 2023-2031.
Biologics are drugs manufactured from organic materials that can treat various disorders, including immune-related illnesses such as Crohn's disease, psoriasis, ankylosing spondylitis, and rheumatoid arthritis. The intriguing feature is that biologics are isolated from various natural sources, whether carbohydrates, proteins, nucleic acids, or a complex mixture of these materials.
The improved understanding of disease's genetic and molecular foundation has paved the way for creating various tailored treatments. Recombinant proteins, for example, help the immune system identify and bind foreign molecules. Advances in manufacturing capability development are expected to increase biopharmaceutical production capacity. The use of single-use systems in the synthesis and processing of biopharmaceuticals is also among these breakthroughs.
However, the COVID-19 pandemic had a large market impact. During the pandemic, there was a huge demand for biologics, which contributed significantly to the market's rise. For example, the National Research Council of Canada and China-based CanSino Biologics collaborated on the development of a COVID-19 vaccine in Canada in May 2020. During the pandemic, the considerable research and development operations for the treatment of COVID-19 contributed considerably to the expansion of the biologics market.
Recent Developments:
- In February 2022, The Janssen Pharmaceutical Companies of Johnson & Johnson obtained the United States Food and Drug Administration (FDA) approval for CARVYKTI (ciltacabtagene autoleucel; cilia-cel). This drug is used to treat adults with refractory or relapsed multiple myeloma (RRMM), including an a proteasome inhibitor, immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Competitive Landscape:
Some of the Biologics Market Players are:
- Abbvie Inc.
- Amgen
- AstraZeneca
- Bayer AG
- Celltrion Inc.
- Addgene
- Eli Lilly & Company
- Hoffmann-La Roche Ltd
- GSK group of companies
- Johnson & Johnson Services, Inc
- Merck & Co. Inc
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc.
- Precision Biologics, Inc.
- Samsung Biologics
- Sanofi
Market Segmentation:
The biologics market is segmented based on source, product, disease, manufacturing, route of administration, drug classification, mode of purchase, distribution channel. Based on source, the market is segmented as microbial, mammalian, and others. The products segment includes MABs, Vaccines, Antisense, RNAi & Molecular Therapy, Recombinant Proteins, Others. By disease category, the market is segmented into Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Others. Manufacturing segment includes Outsourced, In-house, Route of Administration segment includes Oral and Others (IV and IP), Drug Classification segment includes Branded & Generic Drugs, Mode of Purchase segment includes Prescription & Over-The-Counter (OTC) Drugs, and Distribution Channel segment includes Hospital, Retail and online.
Based On The Source, The Microbial Segment Is A Major Contributor To The Biologics Market
The microbial category is expected to hold a major share of the global Biologics Market in 2022. This is attributed to the high number of medications developed by employing these products. Microbial expression systems commonly include E. Coli and yeast. Recombinant insulin, granulocyte-macrophage colony-stimulating factor, platelet-derived growth factor, and recombinant interferon are all products of these expression systems. Companies utilizing microbial systems include Johnson & Johnson, Novartis, and Genentech.
The Oncology Segment Witnessed Growth At A Rapid Rate
The oncology segment is projected to grow at a rapid rate in the global Biologics Market owing to the rising incidence of cancer coupled with the presence of different R&D programs. These efforts include cancer-eradication gene treatments and antisense therapeutics. Additionally, oncology is expected to retain its supremacy during the predicted period. The increased use of goods to lessen the number of adverse effects connected with the use of cancer chemotherapy is one of the drivers for the expected growth.
In The Region, The North America Biologics Market Holds A Significant Revenue Share
The North America Biologics Market is expected to register the highest market share in terms of revenue in the near future. This can be attributed to significant corporations, engaging reimbursement policies, and considerable R&D investment. In the United States, biologics account for around 38% of overall medication spending. Approval of new biologic drugs will likely boost market expansion throughout the projection period; for example, the US FDA approved 21 BLAs in 2021. Because of increased R&D spending for biologic development, as well as the availability of a high number of FDA-approved biologics in the country, the United States market for biologics will account for a considerable proportion in 2021. In addition, Germany holds the largest proportion of the European biologics market.
The presence of a sophisticated manufacturing sector, favorable reimbursement, the availability of several approved medications, and the target patient group all contribute to this market's supremacy in Europe.
Biologics Market Report Scope:
|
Report Attribute |
Specifications |
|
Market size value in 2022 |
USD 382.17 Bn |
|
Revenue forecast in 2031 |
USD 718.97 Bn |
|
Growth rate CAGR |
CAGR of 7.50 % from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Billion, and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Source, Product, Disease, Manufacturing, Route of Administration, Drug Classification, Mode of Purchase, Distribution Channel |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Samsung BioLogics; Amgen; Novo Nordisk A/S; AbbVie Inc.; Sanofi; Pfizer Inc.; Inc.; GSK group of companies; Merck & Co., Celltrion; Precision Biologics, Inc.; Johnson & Johnson Services, Inc; Eli Lilly and Company; Novartis AG; Merck KGaA; Bayer AG; F. Hoffmann-La Roche Ltd; and AstraZeneca |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
